Original ArticlesRETINAL FUNCTION AFTER SUBCONJUNCTIVAL INJECTION OF CARBOPLATIN IN FIBRIN SEALANTPARDUE, MACHELLE T. PhD*†; HEJNY, CHARLES MD*; GILBERT, JAKE A. BS*; PHILLIPS, M JOE BS†; GEROSKI, DAYLE H. PhD*; EDELHAUSER, HENRY F. PhD*Author Information From the *Department of Ophthalmology, Emory University, Atlanta, Georgia; and the †Rehabilitation Research and Development Center, Atlanta Veterans Affairs Medical Center, Decatur, Georgia. Supported in part by NEI Grant T32-EY07092, Foundation Fighting Blindness, Knights Templar, an unrestricted grant from Research to Prevent Blindness, and the Administration of Veterans Affairs. A portion of this work was presented at the annual meeting of the Association for Research in Vision and Ophthalmology, May 5–10, 2002, Ft. Lauderdale, FL. Gilbert JA, Hejny C, Pardue MT, Barnett T, Phillips MJ, Aaberg TM, Geroski DH, Edelhauser HF. Electroretinogram effects of sustained transscleral drug delivery of carboplatin from fibrin sealant [E-Abstract 2587]. Invest Ophthalmol Vis Sci 2002;43:2587. The authors have no proprietary interest in any aspect of this article. Reprint requests: Henry F. Edelhauser, PhD, Emory Eye Center, 1365B Clifton Road NE, Suite B2600, Atlanta, GA 30322; e-mail: [email protected] Retina: October 2004 - Volume 24 - Issue 5 - p 776-782 Buy AbstractIn Brief Purpose: To evaluate retinal function in a rabbit model after subconjunctival delivery of carboplatin in balanced saline solution (BSS) or fibrin sealant to determine possible retinal toxicity. Methods: One group of rabbits (n = 5) received a unilateral subconjunctival injection of 12.2 ± 1.0 mg/mL of carboplatin (Paraplatin) in BSS. Another group of rabbits (n = 5) received 25.1 ± 7.7 mg/mL of carboplatin in fibrin sealant (Hemaseel APR). Rabbits injected with fibrin sealant only (n = 2) and BSS only (n = 2) were used as control groups. Electroretinographic recordings consisted of a series of intensities presented under dark- and light-adapted conditions. Electroretinograms were recorded before the injection (baseline) and 2 days, 1, 2, and 3 weeks after the injection. After 3 weeks, all rabbit eyes were obtained for histopathologic examination. Results: Transient reductions in the dark-adapted b-wave amplitudes were noted 2 days after treatment for eyes injected with carboplatin compared with the vehicle-only treatment groups. Other treatment groups and postinjection time points showed no significant changes from baseline. Retinal structure and thickness were normal 3 weeks after treatment for all treatment groups. Conclusion: Subconjunctival delivery of carboplatin in fibrin sealant or BSS does not have a toxic effect on retinal function or structure in a non-tumor-bearing rabbit model at the doses used in this study at 3 weeks’ follow-up. Subconjunctival injections of carboplatin in BSS or fibrin sealant were formed in a rabbit model. ERG recordings taken for 3 weeks after treatment indicate a transient decrease in retinal function after injection that returns to baseline values by 1 week postinjection. © The Ophthalmic Communications Society, Inc.